News
Sarepta Shares Dive on Second Fatal Liver Failure Tied to Elevidys
Sarepta Therapeutics shares dived 42% in premarket trading after the company disclosed a second reported case of acute liver failure that resulted in a death tied to its Duchenne muscular dystrophy treatment Elevidys. Shares were trading around $20.61. The stock is down 70% on the year.
Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular ...
Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of ...
Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene ...
4hon MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...
Sarepta Therapeutics Inc. said a second patient has died of acute liver failure after being treated with its gene therapy for ...
Sarepta Therapeutics shares plunged 36% after the company reported a second case of acute liver failure resulting in death from taking Elevidys, which is a gene therapy for patients with Duchenne ...
Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback